Overview: Lyme Disease IgG/IgM Immunoblot TestIntroduction: The Lyme Disease IgG/IgM Immunoblot Test detects Borrelia IgG and IgM to diagnose Lyme disease, causing fatigue or neurological symptoms. Aligned with 2023 IDSA guidelines, it uses immunoassay for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected Lyme disease.
Other Names: Lyme IgG/IgM Assay, Borrelia Immunoblot Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Lyme serology testing began in the 1980s with Lyme disease research. Immunoblot methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Borrelia IgG and IgM to diagnose Lyme disease, guides treatment, and evaluates patients with fatigue or neurological symptoms.
Test Parameters: 1. Borrelia IgG and IgM Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of fatigue, neurological symptoms, or tick exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, neurological symptoms, joint pain, or history of tick exposure. Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, Lyme disease implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunoassay (immunoblot) to detect Borrelia IgG and IgM in serum or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Lyme disease diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive IgG/IgM confirms Lyme disease, guiding antibiotic therapy. Negative results may require PCR or further testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Lyme PCR, ELISA, or Western blot to confirm Lyme disease diagnosis.
Test Limitations: Early infection may yield false negatives; clinical correlation is needed. Cross-reactivity with other spirochetes may occur.
References: IDSA Lyme Disease Guidelines, 2023; Clinical Infectious Diseases, Wormser GP, 2022.
